A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.
In a prospective, open-label pilot study in probable-Alzheimer disease (AD) outpatients, the authors investigated the efficacy of citalopram to reduce restless activity and aberrant motor behaviors. Nineteen subjects were evaluated with Neuropsychiatric Inventory subscale and total scores. There was a significant decline in aberrant motor behaviors and overall behavior problems at 4, 8, and 12 weeks. This study provides initial evidence that citalopram may be effective in reducing aberrant motor behaviors in AD. However, because of the potential biases of an open-label study, these findings need to be confirmed in a larger, controlled trial.